{"id":"r-pola-mini-chp","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This regimen pairs rituximab, a CD20-targeting monoclonal antibody, with a mini-chemotherapy combination (mini-CHP: cyclophosphamide, doxorubicin, and prednisone at reduced doses) to achieve anti-lymphoma efficacy while minimizing cumulative toxicity. The rituximab component provides targeted B-cell depletion, while the reduced-dose chemotherapy provides additional cytotoxic activity, making it suitable for elderly or frail patients with lymphoma.","oneSentence":"R-pola-mini-CHP is a mini-chemotherapy regimen combining rituximab with a reduced-intensity chemotherapy backbone (mini-CHP) designed to treat lymphoma with lower toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:07.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diffuse large B-cell lymphoma (DLBCL) in elderly or frail patients"}]},"trialDetails":[{"nctId":"NCT06828991","phase":"PHASE2","title":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","status":"RECRUITING","sponsor":"Danielle Wallace","startDate":"2025-09-04","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":40},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT04332822","phase":"PHASE3","title":"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma","status":"RECRUITING","sponsor":"Nordic Lymphoma Group","startDate":"2020-08-19","conditions":"DLBCL, Diffuse Large B Cell Lymphoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-pola-mini-CHP","genericName":"R-pola-mini-CHP","companyName":"Nordic Lymphoma Group","companyId":"nordic-lymphoma-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-pola-mini-CHP is a mini-chemotherapy regimen combining rituximab with a reduced-intensity chemotherapy backbone (mini-CHP) designed to treat lymphoma with lower toxicity. Used for Diffuse large B-cell lymphoma (DLBCL) in elderly or frail patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}